Finding markers of good response to fcRn inhibitors in myasthenia gravis
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This study looks for markers that might predict who will respond well to a new class of medicines called FcRn inhibitors. These medicines help reduce harmful antibodies that attack nerves and muscles in people with a certain type of Myasthenia Gravis. The goal is to better personalize treatment for patients in Italy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with generalized anti-AChR positive Myasthenia Gravis (a specific type of this muscle-weakening disease).
- Your doctor has prescribed a new type of medicine called an FcRn inhibitor (like efgartigimod or rozanolixizumab) for your Myasthenia Gravis.
- You are able to keep follow-up appointments at the study center.
- You do not have other autoimmune diseases, active cancer, or a serious infection right now.
- You are willing to sign a consent form to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for markers that may predict a favorable response to complement inhibitor drugs in people with generalized myasthenia gravis. It aims to identify who might benefit most from this treatment.
This study uses lab-grown mini muscle-nerve cells (organoids) to better understand severe, hard-to-treat myasthenia gravis. It may help researchers find new treatment options for people with the AChR antibody type.
This study tests a new drug called aritinercept to see if it can help people with generalized myasthenia gravis (a condition where muscles weaken over time). Researchers believe this drug may reduce the immune system activity that causes muscle weakness.
This study uses wearable sensors and smartphone apps to track your myasthenia gravis symptoms over time. It aims to see how well these technologies can measure your condition in daily life, which could help you and your doctor manage your care better.
This Phase 3 trial tests rituximab (an immune system medicine) to see if it improves myasthenia gravis (MG) symptoms and function. It’s for adults with confirmed MG and moderate-to-severe impact on daily activities despite current care.
This trial tests whether tocilizumab can improve symptoms and safety in people with generalized myasthenia gravis (MG) who already take standard MG treatments. It may help if your weakness is still significant despite current therapy.
Hear when a new Myasthenia Gravis Generalized trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.